-- Alexander Kolevzon, M.D., to review additional data from company’s Phase 2 STARS trial with OV101 for the treatment of Angelman syndrome during the 65^th American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting --

NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will host a conference call and webcast on Thursday, October 25, at 10:30 a.m. EDT. Alexander Kolevzon, M.D., professor of psychiatry and pediatrics at the Icahn School of Medicine at Mount Sinai, will join members of Ovid’s management team in reviewing additional data from the company’s Phase 2 STARS trial with OV101 for the treatment of Angelman syndrome, a genetic disorder with no approved therapies.

The additional data will also be presented in a poster titled “STARS: Results from a Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-blind, Safety and Efficacy Study of OV101” at AACAP taking place from October 22-27 in Seattle, Washington.

The live webcast of the conference call may be accessed by visiting the Investors section of the company's website at investors.ovidrx.com. Alternatively, please call (866) 830-1640 (U.S.) or (210) 874-7820 (international) to listen to the live conference call. The conference ID number for the live call is 7685159. An archive of the webcast will be available for at least two weeks on the company’s website.

Poster Presentation Details
Title: STARS: Results from a Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-blind, Safety and Efficacy Study of OV101
Session: New Research Poster Session 3
Date/Time: Thursday, October 25, 2018 at 9:30 a.m. PDT (12:30 p.m. EDT)
Location: Washington State Convention Center, Seattle, Washington

About Ovid Therapeutics
Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s lead investigational medicine, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK-935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE).

For more information on Ovid, please visit http://www.ovidrx.com/.

Contacts
Investors:
Lora Pike  
Ovid Therapeutics Inc.
lpike@ovidrx.com

Jill Steier
Burns McClellan, Inc
jsteier@burnsmc.com
(212) 213-0006

Media:
Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.